Antifungal susceptibility testing practices in mycology laboratories in France, 2018

A survey of mycology laboratories for antifungal susceptibility testing (AFST) was undertaken in France in 2018, to better understand the difference in practices between the participating centers and to identify the difficulties they may encounter as well as eventual gaps with published standards and guidelines. The survey captured information from 45 mycology laboratories in France on how they perform AFST (number of strains tested, preferred method, technical and quality aspects, interpretation of the MIC values, reading and interpretation difficulties). Results indicated that 86% of respondents used Etest as AFST method, with a combination of one to seven antifungal agents tested. Most of the participating laboratories used similar technical parameters to perform their AFST method and a large majority used, as recommended, internal and external quality assessments. Almost all the participating mycology laboratories (98%) reported difficulties to interpret the MIC values, especially when no clinical breakpoints are available. The survey highlighted that the current AFST practices in France need homogenization, particularly for MIC reading and interpretation.     

The T2Bacteria Assay Is a Sensitive and Rapid Detector of Bacteremia That Can Be Initiated in the Emergency Department and Has Potential to Favorably Influence Subsequent Therapy

BackgroundBacteremia causes a major worldwide burden, in terms of financial and productivity costs, as well the morbidity and mortality it can ultimately cause. Proper treatment of bacteremia is a challenge because of the species-dependent response to antibiotics. The T2Bacteria Panel is a U.S. Food and Drug Administration–cleared and culture-independent assay for detection of bacteremia, including common ESKAPE pathogens—Escherichia coli, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa—and provides species identification in as little as 3.6 h directly from blood.ObjectiveOur aim was to evaluate the T2Bacteria assay performance and potential to affect patient care in the emergency department (ED).MethodsED patients from a Louisiana and Florida center were enrolled as part of the T2Bacteria Panel clinical study, which was prospective and noninterventional. Blood samples for blood culture (BC) and T2Bacteria were matched in time and anatomic location.ResultsData from 137 ED patients were evaluated. Relative to BC, T2Bacteria showed 100% positive percent agreement and 98.4% negative percent agreement. In addition, for species on the T2Bacteria Panel, the T2Bacteria assay detected 25% more positives associated with infection, and on average identified the infectious species 56.6 h faster. The T2Bacteria assay covered 70.5% of all species detected by BC. Finally, relative to actual care, the T2Bacteria assay could have potentially focused therapy in 8 patients, reduced time to a species-directed therapy in 4 patients, and reduced time to effective therapy in 4 patients.ConclusionsIn this ED population, the T2Bacteria assay was a rapid and sensitive detector of bacteremia from common ESKAPE pathogens and showed the theoretical potential to influence subsequent patient therapy, ranging from antibiotic de-escalation to faster time to effective therapy.     

Enhancing laboratory report contents to improve outpatient management of test results

In today''s environment, providers are extremely time-constrained. Assembling relevant contextual data to make decisions on laboratory results can take a significant amount of time from the day. The Regenstrief Institute has created a system which leverages data within Indiana Health Information Exchange''s (IHIE''s) repository, the Indiana Network for Patient Care (INPC), to provide well-organized and contextual information on returning laboratory results to outpatient providers. The system described here uses data extracted from INPC to add historical test results, medication-dispensing events, visit information, and clinical reminders to traditional laboratory result reports. These “Enhanced Laboratory Reports” (ELRs) are seamlessly delivered to outpatient practices connected through IHIE via the DOCS4DOCS clinical messaging service. All practices, including those without electronic medical record systems, can receive ELRs. In this paper, the design and implementation issues in creating this system are discussed, and generally favorable preliminary results of attitudes by providers towards ELRs are reported.     

化学品环境管理与水生实验动物

从分析化学品的特性入手，在概述化学品的环境管理对水生实验生物需求和国内外水生实验生物发展现状的基础上，从加强化学品环境管理的科学基础建设出发，对我国水生实验生物的研究与发展的标准化、产业化、必要的资质认可及信息交流提出建议。     

MRI诊断子宫腺肌病的价值

目的 探讨MRI诊断子宫腺肌病的价值.方法 回顾性分析6例子宫腺肌病患者MRI和超声检查的资料,与术后病理结果对比,评估MRI对子宫腺肌病的诊断符合率.结果 B超诊断子宫腺肌病的灵敏度为52.5%、特异度为54.2%;MRI灵敏度为95.6%、特异度为100%;MRI检查既能定性,又能定位,而且此检查无创伤,方便快捷.结论 MRI为临床诊断子宫腺肌病提供了一种有价值的检查方法,对及时、正确治疗该病具有重要的临床意义.     

兔腹主动脉球囊成形术后狭窄过程中内皮素的动态变化及卡托普利的治疗作用

目的　观察内膜损伤后血管狭窄的主要病理变化和此过程中血浆内血管内皮素(endothelin ,ET)水平的动态变化及局部动脉组织内ET反应性 (ET immunoreaction ,ET IR) ,探讨卡托普利 (Captopril)对动脉球囊损伤后狭窄的影响。方法　大耳白兔 4 8只 ,依术后处死时间不同 (6h和 1、3、7、15、2 2d)按随机表法随机分为 6组 ,每组 8只 ,其中 3只为内膜损伤 (手术组 )、3只为损伤 卡托普利治疗 (治疗组 ) ,2只为对照组。术前及术后均采静脉血 ,手术组及治疗组置入微球囊导管于腹主动脉内制备内膜损伤模型。治疗组术前 1d给予卡托普利 2mg·kg-1·d-1直至处死当日。放射免疫法检测术前、术后血浆内ET水平 ,处死后取模型动脉血管 ,观察血管内膜厚度及管腔病理变化 ,免疫组织化学法检测动脉组织内ET反应。结果　手术组各时间段血浆ET水平 [平均值 (139 17± 16 86 )ng/L) ]和治疗组各时间段血浆ET水平 [平均值 (12 2 16± 13 5 6 )ng/L]均较术前 [平均值 (111 2 4±11 39)ng/L]升高 (P <0 0 1和P <0 0 5 ) ,手术组术后各时间段血浆ET水平比治疗组及对照组有明显升高 (P值均 <0 0 1) ,而治疗组与对照组术后血浆ET水平无显著性差异 ;手术组动脉内膜有不同程度增厚 ,主要以血管平滑肌细胞 (vascularsmoothmusclec     

创伤性颅眶畸形的三维可视化诊断分析与手术整复

目的：依据颅眶创伤畸形诊断分类选择相应术式予以整复，并通过规范化治疗改善整复疗效。方法：81例创伤性颅眶畸形均经三维cT确诊为颅-眶-颧颌骨折和畸形。将其分为适合于选择手术术式的四类：①颅骨缺损；②眶壁爆裂骨折；③普通眶周骨折；④复杂眶周骨折。结果：①颅骨缺损12例（14．8％），采用自体肋骨或颅骨板移植获得良效；②眶壁爆裂骨折16例（19．7％），手术还纳眶内容、封闭疝孔、恢复眶腔容积和眼球位置；③普通眶周骨折21例（25．8％）：以骨缺损形态体积相同的骨组织修复，无骨质缺损者则截骨，使骨折段复位固定；④复杂眶周骨折32例（39．5％）：截断错位愈合的骨折线将眶-颧-颌复合体复位；眶粉碎者，应用CAD／CAM快速成型技术预制人工骨眶，手术效果良好。本组所有病例未出现植骨坏死、外露、畸形复发、眶内血肿等严重并发症。结论：颅骨缺损的整复仍以自体骨移植、钛网修复效果较好。眶爆裂骨折晚期畸形以植入自体骨或人工骨修复骨缺损、矫正复视、眼球复位为主。普通眶周骨折：采取截骨、植骨或生物材料植入修复的手术方案。复杂眶周骨折晚期畸形最有效的方法是截断错位愈合的骨折段，复位颅面骨结构形态。典型的Le Fort型骨折，宜采用Le FortⅠ～Ⅲ型截骨手术。